The aim of this retrospective study was to detail the main clinicopathological characteristics of advanced cancer patients exhibiting hyperprogressive disease (HPD) during immune checkpoint inhibitor (ICI) nivolumab as second- or third-line treatment. A cohort of patients starting second or third-line nivolumab for advanced cancer from 2016 to 2018 was identified from our institution IRB approved and prospectively collected registry. HPD was defined as at least two-fold increase in the tumor growth rate (TGR) during immunotherapy compared to TGR during the preimmunotherapy period. Overall, 47 patients were eligible for this analysis. HPD was observed in three patients (6%) with metastatic lung adenocarcinoma, metastatic urothelial transitio...
In the immunotherapy era, considering the prolonged survival benefit and responses observed with imm...
Purpose Although immune-checkpoint inhibitors (ICIs) have emerged as therapeutic options for recurre...
Immune checkpoint inhibitors have revolutionized cancer treatment with patient improved survival, qu...
The aim of this retrospective study was to detail the main clinicopathological characteristics of ad...
[[abstract]]Background Retrospective studies have suggested a potential risk of hyperprogressive dis...
Background & aims: Programmed cell death-1 (PD-1) inhibitor treatment can cause hyperprogressive dis...
Introduction The increased use of new checkpoint inhibitors in cancer therapy has led to the discove...
International audienceIntroduction: Immune checkpoint inhibitors (ICIs) have revolutionised cancer c...
Background. Nowadays, PD-1/PD-L1 inhibitors are widely used to treat various malignant tumors. Howev...
BACKGROUND: Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been...
Objective: Update the last known review, and summarize the definitions, diagnostic criteria, reporte...
Immunotherapy, which takes advantage of the immune system to eliminate cancer cells, has been widely...
The occurrence of markedly accelerated tumor growth during immunotherapy is considered a new mode of...
There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various ...
Introduction: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSC...
In the immunotherapy era, considering the prolonged survival benefit and responses observed with imm...
Purpose Although immune-checkpoint inhibitors (ICIs) have emerged as therapeutic options for recurre...
Immune checkpoint inhibitors have revolutionized cancer treatment with patient improved survival, qu...
The aim of this retrospective study was to detail the main clinicopathological characteristics of ad...
[[abstract]]Background Retrospective studies have suggested a potential risk of hyperprogressive dis...
Background & aims: Programmed cell death-1 (PD-1) inhibitor treatment can cause hyperprogressive dis...
Introduction The increased use of new checkpoint inhibitors in cancer therapy has led to the discove...
International audienceIntroduction: Immune checkpoint inhibitors (ICIs) have revolutionised cancer c...
Background. Nowadays, PD-1/PD-L1 inhibitors are widely used to treat various malignant tumors. Howev...
BACKGROUND: Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been...
Objective: Update the last known review, and summarize the definitions, diagnostic criteria, reporte...
Immunotherapy, which takes advantage of the immune system to eliminate cancer cells, has been widely...
The occurrence of markedly accelerated tumor growth during immunotherapy is considered a new mode of...
There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various ...
Introduction: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSC...
In the immunotherapy era, considering the prolonged survival benefit and responses observed with imm...
Purpose Although immune-checkpoint inhibitors (ICIs) have emerged as therapeutic options for recurre...
Immune checkpoint inhibitors have revolutionized cancer treatment with patient improved survival, qu...